论文部分内容阅读
本研究旨在评价吸入性皮质类固醇对哮喘患者气道炎症及症状的影响。病人和方法 10例变应性哮喘患者平均年龄24.9岁,均接受过吸入性舒喘灵治疗,且因病情较重需预防性抗炎治疗。首先,所有患者吸入100μg 舒喘灵共2周;然后,吸入二丙酸倍氯美松(BDP)500μg 每天4次,共2周,接着吸入 BDP500μg 每天2次,共4周。治疗期间详细记录舒喘灵使用情况及哮喘严重度,并测定最大呼气流速(PEF)和1秒钟用力呼气量(FEV_1)等。于 BDP 治疗前和治疗结束后对所有患者行纤维支气管镜活检术;活检的支气管标本通过
This study was designed to evaluate the effects of inhaled corticosteroids on airway inflammation and symptoms in asthmatic patients. Patients and Methods 10 patients with allergic asthma average age of 24.9 years old, have received inhaled salbutamol treatment, and due to serious illness need prophylactic anti-inflammatory treatment. First, 100 μg of salbutamol was inhaled for 2 weeks in all patients; then 500 μg of beclomethasone dipropionate (BDP) was inhaled 4 times a day for 2 weeks followed by 500 μg of BDP twice a day for 4 weeks. During treatment, the use of salbutamol and the severity of asthma were recorded in detail, and the maximum expiratory flow (PEF) and forced expiratory volume per 1 second (FEV_1) were measured. All patients underwent fibrobronchial biopsy before and after treatment with BDP; bronchial specimens biopsied